J. Safra Sarasin Holding AG Acquires 13,299 Shares of DexCom, Inc. $DXCM

J. Safra Sarasin Holding AG lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 57.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,283 shares of the medical device company’s stock after buying an additional 13,299 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in DexCom were worth $2,408,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Twin Peaks Wealth Advisors LLC purchased a new position in DexCom during the 2nd quarter valued at $26,000. SJS Investment Consulting Inc. increased its stake in DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares during the period. Financial Consulate Inc. bought a new stake in shares of DexCom during the third quarter worth $29,000. CVA Family Office LLC lifted its position in shares of DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the last quarter. Finally, ORG Partners LLC boosted its stake in shares of DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 281 shares during the period. 97.75% of the stock is owned by institutional investors.

DexCom Stock Up 1.5%

Shares of NASDAQ DXCM opened at $62.80 on Wednesday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The stock’s fifty day simple moving average is $69.75 and its two-hundred day simple moving average is $67.37. The stock has a market capitalization of $24.17 billion, a PE ratio of 29.90, a price-to-earnings-growth ratio of 1.21 and a beta of 1.48. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.65 by $0.03. The firm had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.45 EPS. As a group, analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $64.85, for a total value of $110,245.00. Following the completion of the transaction, the executive vice president directly owned 112,904 shares in the company, valued at approximately $7,321,824.40. The trade was a 1.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DXCM. Mizuho upped their price target on shares of DexCom from $78.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, February 13th. Truist Financial reissued a “buy” rating and issued a $80.00 price objective (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Leerink Partners restated an “outperform” rating and issued a $92.00 target price on shares of DexCom in a research note on Tuesday, December 16th. Canaccord Genuity Group set a $95.00 target price on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, February 13th. Finally, BTIG Research reaffirmed a “buy” rating and set a $85.00 price target on shares of DexCom in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $86.50.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.